CNCR vs. XPH

Last updated Jun 3, 2026

CNCR (Loncar Cancer Immunotherapy ETF) and XPH (SPDR S&P Pharmaceuticals ETF) are both Health & Biotech Equities funds - CNCR tracks the Loncar Cancer Immunotherapy Index while XPH tracks the S&P Pharmaceuticals Select Industry Index. Both are passively managed. CNCR charges 0.79%/yr vs 0.35%/yr for XPH.

Performance

CNCR vs. XPH - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Loncar Cancer Immunotherapy ETF (CNCR) and SPDR S&P Pharmaceuticals ETF (XPH). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

CNCR

• 1D: 0.00%
• 1M: 0.00%
• YTD: —
• 6M: —
• 1Y: —
• 3Y*: —
• 5Y*: —
• 10Y*: —

XPH

• 1D: -2.94%
• 1M: -4.77%
• YTD: -0.44%
• 6M: 6.13%
• 1Y: 36.88%
• 3Y*: 12.65%
• 5Y*: 3.24%
• 10Y*: 3.33%

*Multi-year figures are annualized to reflect compound growth (CAGR)

CNCR vs. XPH - Yearly Performance Comparison

	2026 (YTD)
CNCR Loncar Cancer Immunotherapy ETF	0.00%
XPH SPDR S&P Pharmaceuticals ETF	-2.63%

CNCR vs. XPH - Sectors Allocation Comparison

Sectors	CNCR	XPH
Healthcare	96.6%	100.0%
Financial Services	3.3%	-
Basic Materials	-	-
Communication Services	-	-
Consumer Cyclical	-	-
Consumer Defensive	-	-
Energy	-	-
Industrials	-	-
Real Estate	-	-
Technology	-	-
Utilities	-	-

Return for Risk

CNCR vs. XPH — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

XPH

XPH Risk / Return Rank: 54
XPH Sharpe Ratio Rank: 49
XPH Sortino Ratio Rank: 50
XPH Omega Ratio Rank: 45
XPH Calmar Ratio Rank: 63
XPH Martin Ratio Rank: 63

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

CNCR vs. XPH - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Loncar Cancer Immunotherapy ETF (CNCR) and SPDR S&P Pharmaceuticals ETF (XPH). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Risk / return metrics aren't available yet — we need at least 12 months of trading data to calculate them.

Sharpe Ratios by Period

	CNCR	XPH	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	—	1.72	—
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	—	0.16	—
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	—	0.15	—
Sharpe Ratio (All Time) Calculated using the full available price history	—	0.38	—

Drawdowns

CNCR vs. XPH - Drawdown Comparison

The maximum CNCR drawdown since its inception was 0.00%, smaller than the maximum XPH drawdown of -48.03%. Use the drawdown chart below to compare losses from any high point for CNCR and XPH.

Drawdown Indicators

	CNCR	XPH	Difference
Max Drawdown Largest peak-to-trough decline	0.00%	-48.03%	+48.03%
Max Drawdown (1Y) Largest decline over 1 year	—	-11.97%	—
Max Drawdown (3Y) Largest decline over 3 years	—	-23.57%	—
Max Drawdown (5Y) Largest decline over 5 years	—	-31.63%	—
Max Drawdown (10Y) Largest decline over 10 years	—	-35.97%	—
Current Drawdown Current decline from peak	0.00%	-8.24%	+8.24%
Average Drawdown Average peak-to-trough decline	0.00%	-17.25%	+17.25%
Ulcer Index Depth and duration of drawdowns from previous peaks	—	3.32%	—

Volatility

Volatility by Period

	CNCR	XPH	Difference
Volatility (1M) Calculated over the trailing 1-month period	—	7.03%	—
Volatility (6M) Calculated over the trailing 6-month period	—	16.85%	—
Volatility (1Y) Calculated over the trailing 1-year period	0.00%	21.52%	-21.52%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	0.00%	20.84%	-20.84%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	0.00%	22.10%	-22.10%

CNCR vs. XPH - Expense Ratio Comparison

CNCR has a 0.79% expense ratio, which is higher than XPH's 0.35% expense ratio.

Dividends

CNCR vs. XPH - Dividend Comparison

CNCR has not paid dividends to shareholders, while XPH's dividend yield for the trailing twelve months is around 0.67%.

Position	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
CNCR Loncar Cancer Immunotherapy ETF	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
XPH SPDR S&P Pharmaceuticals ETF	0.67%	0.83%	1.58%	1.28%	1.64%	0.95%	0.47%	0.64%	0.65%	0.67%	0.63%	7.15%

Frequently Asked Questions

Which ETF is better, CNCR or XPH?

On fees, XPH is cheaper at 0.35% per year. The better choice depends on whether you care most about return, fees, risk, or income.

Which ETF is cheaper, CNCR or XPH?

XPH is cheaper with a 0.35% expense ratio, compared with 0.79% for CNCR.

Which ETF pays a higher dividend yield, CNCR or XPH?

XPH has the higher dividend yield at 0.67%, compared with 0.00% for CNCR.

What is the main difference between CNCR and XPH?

CNCR tracks Loncar Cancer Immunotherapy Index, while XPH tracks S&P Pharmaceuticals Select Industry Index. They also come from different issuers: Exchange Traded Concepts and State Street. Their fees differ too: 0.79% for CNCR and 0.35% for XPH.